MHCD0817

antibody from Invitrogen Antibodies

Targeting: CD8B CD8B1

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MHCD0817

Provider

Invitrogen Antibodies

Product name

CD8 Monoclonal Antibody (3B5), PE-Texas Red

Antibody type

Monoclonal

Antigen

Other

Description

The R-phycoerythrin (PE)-Texas Red conjugate permits simultaneous multicolor labeling and detection of multiple targets with excitation by a single excitation source-the 488 nm line of the argon-ion laser.

Antibody clone number

3B5

References

Submitted references

A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.

Li C, Phoon YP, Karlinsey K, Tian YF, Thapaliya S, Thongkum A, Qu L, Matz AJ, Cameron M, Cameron C, Menoret A, Funchain P, Song JM, Diaz-Montero CM, Tamilselvan B, Golden JB, Cartwright M, Rodriguez A, Bonin C, Vella A, Zhou B, Gastman BR
The Journal of experimental medicine 2022 Jan 3;219(1)

---

Protein/AS01(B) vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors.

Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doeleman SE, Chen Y, Silk SE, Barrett JR, Elias SC, Miura K, Diouf A, Bardelli M, Dabbs RA, Barfod L, Long CA, Haynes BF, Payne RO, Minassian AM, Bradley T, Draper SJ, Borrow P
Cell reports. Medicine 2021 Mar 16;2(3):100207

---

Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.

Cai F, Chen WH, Wu W, Jones JA, Choe M, Gohain N, Shen X, LaBranche C, Eaton A, Sutherland L, Lee EM, Hernandez GE, Wu NR, Scearce R, Seaman MS, Moody MA, Santra S, Wiehe K, Tomaras GD, Wagh K, Korber B, Bonsignori M, Montefiori DC, Haynes BF, de Val N, Joyce MG, Saunders KO
PLoS pathogens 2021 Jun;17(6):e1009624

---

Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer.

Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, Lameiras S, Albergante L, Bonneau C, Guyard A, Tarte K, Zinovyev A, Baulande S, Zalcman G, Vincent-Salomon A, Mechta-Grigoriou F
Cancer discovery 2020 Sep;10(9):1330-1351

---

Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations.

Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO
Nature communications 2019 Jul 1;10(1):2898

---

Correlation of APRIL with production of inflammatory cytokines during acute malaria in the Brazilian Amazon.

Pinna RA, Dos Santos AC, Perce-da-Silva DS, da Silva LA, da Silva RNR, Alves MR, Santos F, de Oliveira Ferreira J, Lima-Junior JC, Villa-Verde DM, De Luca PM, Carvalho-Pinto CE, Banic DM
Immunity, inflammation and disease 2018 Jun;6(2):207-220

---

Non-conventional Inhibitory CD4(+)Foxp3(-)PD-1(hi) T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD
Cancer cell 2018 Jun 11;33(6):1017-1032.e7

---

Predictive value of human cytomegalovirus (HCMV) T-cell response in the control of HCMV infection by seropositive solid-organ transplant recipients according to different assays and stimuli.

Gabanti E, Bruno F, Scaramuzzi L, Mangione F, Zelini P, Gerna G, Lilleri D
The new microbiologica 2016 Oct;39(4):247-258

---

Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.

Yadav A, Betts MR, Collman RG
Journal of neurovirology 2016 Oct;22(5):584-596

---

Targeting CD8(+) T cells prevents psoriasis development.

Di Meglio P, Villanova F, Navarini AA, Mylonas A, Tosi I, Nestle FO, Conrad C
The Journal of allergy and clinical immunology 2016 Jul;138(1):274-276.e6

---

Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand.

Tomić A, Varanasi PR, Golemac M, Malić S, Riese P, Borst EM, Mischak-Weissinger E, Guzmán CA, Krmpotić A, Jonjić S, Messerle M
PLoS pathogens 2016 Dec;12(12):e1006015

---

Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues.

He T, Brocca-Cofano E, Gillespie DG, Xu C, Stock JL, Ma D, Policicchio BB, Raehtz KD, Rinaldo CR, Apetrei C, Jackson EK, Macatangay BJ, Pandrea I
Journal of virology 2015 Sep;89(18):9616-30

---

Plasmacytoid dendritic cells promote HIV-1-induced group 3 innate lymphoid cell depletion.

Zhang Z, Cheng L, Zhao J, Li G, Zhang L, Chen W, Nie W, Reszka-Blanco NJ, Wang FS, Su L
The Journal of clinical investigation 2015 Sep;125(9):3692-703

---

Comparable Genital Tract Infection, Pathology, and Immunity in Rhesus Macaques Inoculated with Wild-Type or Plasmid-Deficient Chlamydia trachomatis Serovar D.

Qu Y, Frazer LC, O'Connell CM, Tarantal AF, Andrews CW Jr, O'Connor SL, Russell AN, Sullivan JE, Poston TB, Vallejo AN, Darville T
Infection and immunity 2015 Oct;83(10):4056-67

---

Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice.

Li G, Cheng M, Nunoya J, Cheng L, Guo H, Yu H, Liu YJ, Su L, Zhang L
PLoS pathogens 2014 Jul;10(7):e1004291

---

Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.

Vanderford TH, Slichter C, Rogers KA, Lawson BO, Obaede R, Else J, Villinger F, Bosinger SE, Silvestri G
Blood 2012 Jun 14;119(24):5750-7

---

CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Taaffe JE, Bosinger SE, Del Prete GQ, Else JG, Ratcliffe S, Ward CD, Migone T, Paiardini M, Silvestri G
Journal of medical primatology 2012 Feb;41(1):24-42

---

Distinct expression patterns of CD69 in mucosal and systemic lymphoid tissues in primary SIV infection of rhesus macaques.

Wang X, Xu H, Alvarez X, Pahar B, Moroney-Rasmussen T, Lackner AA, Veazey RS
PloS one 2011;6(11):e27207

---

Simian immunodeficiency virus infection in rhesus macaques induces selective tissue specific B cell defects in double positive CD21+CD27+ memory B cells.

Das A, Veazey RS, Wang X, Lackner AA, Xu H, Pahar B
Clinical immunology (Orlando, Fla.) 2011 Sep;140(3):223-8

---

Efficient infection, activation, and impairment of pDCs in the BM and peripheral lymphoid organs during early HIV-1 infection in humanized rag2⁻/⁻γ C⁻/⁻ mice in vivo.

Zhang L, Jiang Q, Li G, Jeffrey J, Kovalev GI, Su L
Blood 2011 Jun 9;117(23):6184-92

---

Double-positive CD21+CD27+ B cells are highly proliferating memory cells and their distribution differs in mucosal and peripheral tissues.

Das A, Xu H, Wang X, Yau CL, Veazey RS, Pahar B
PloS one 2011 Jan 27;6(1):e16524

---

Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders.

Foster B, Foroughi S, Yin Y, Prussin C
Clinical and molecular allergy : CMA 2011 Apr 28;9(1):7

---

Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas.

Mehra S, Pahar B, Dutta NK, Conerly CN, Philippi-Falkenstein K, Alvarez X, Kaushal D
PloS one 2010 Aug 31;5(8):e12266

---

Intestinal double-positive CD4+CD8+ T cells of neonatal rhesus macaques are proliferating, activated memory cells and primary targets for SIVMAC251 infection.

Wang X, Das A, Lackner AA, Veazey RS, Pahar B
Blood 2008 Dec 15;112(13):4981-90

---

Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV.

Pahar B, Cantu MA, Zhao W, Kuroda MJ, Veazey RS, Montefiori DC, Clements JD, Aye PP, Lackner AA, Lovgren-Bengtsson K, Sestak K
Vaccine 2006 Nov 17;24(47-48):6839-49

---

Peripheral immature CD2-/low T cell development from type 2 to type 1 cytokine production.

Loza MJ, Perussia B
Journal of immunology (Baltimore, Md. : 1950) 2002 Sep 15;169(6):3061-8

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Human peripheral blood lymphocytes were stained usingPE-Texas Red® of anti-human CD8 monoclonal antibody (clone 3B5). The negative control profiles represent unstained cells.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 PfRH5 vaccination with the ChAd63-MVA platform induces greater activation of total circulating CD8 + and CD4 + T cell populations, while the protein/AS01 B platform elicits a more sustained increase in cTfh-phenotype cells PBMCs from days 0, 7, 14, and 63 were stained ex vivo and analyzed using the gating strategies shown in Figures S1-S3 . (A and B) Increases at day 63 in activated CD38 + Ki67 + cells within total CD8 + and CD4 + T cells (A) or Th1 (CXCR3 + CCR6 - ), Th2 (CXCR3 - CCR6 - ), and Th17 (CXCR3 - CCR6 + ) CD4 + T cell subsets (B) were compared between platforms following subtraction of day 0 CD38 + Ki67 + frequencies in paired samples. (C-E) Frequencies of total cTfh cells defined as CXCR5 + (C) or CXCR5 + PD1 + (D) cells within the CD45RA - CD4 + T cell population were compared between platforms and the frequency of cTfr cells within total cTfh cells (defined as the CD25 + Foxp3 + subset) (E). All of the available samples are plotted (ChAd63-MVA/protein/AS01 B ): day 0, n = 15/54; day 7, n = 15/24; day 14, n = 15/54; day 63, n = 12/20. For intra-trial comparisons (E), only vaccinees with all 4 time points were analyzed: ChAd63-MVA, n = 12, protein/AS01 B , n = 17. Comparisons were performed with Mann-Whitney tests (between trials) or Friedman tests with Dunn's correction for multiple comparisons (within trials comparing day 0 to post-vaccination time points). *p < 0.5, **p < 0.01, and ***p < 0.001. In all of the panels, each point represents a vaccinee.